about
Lost in Translation (LiT): IUPHAR Review 6Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formationThalidomide-induced teratogenesis: history and mechanismsThe potential of the European network of congenital anomaly registers (EUROCAT) for drug safety surveillance: a descriptive studyThe puzzle of autism: an ophthalmologic contributionEpidemiological surveillance of birth defects compatible with thalidomide embryopathy in BrazilThe Quebec Pregnancy Cohort--prevalence of medication use during gestation and pregnancy outcomesThe thalidomide-binding domain of cereblon defines the CULT domain family and is a new member of the β-tent foldTranscriptomic characterization of C57BL/6 mouse embryonic stem cell differentiation and its modulation by developmental toxicantsBiomarkers, metabonomics, and drug development: can inborn errors of metabolism help in understanding drug toxicity?Congenital aberrant tearing: a re-lookComparison of rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on the nature and severity of developmental effects.Stemina biomarker discovery.Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses.Thalidomide: the tragedy of birth defects and the effective treatment of disease.Epidemiology of cardiovascular malformations: prevalence and risk factors.Management of thalidomide toxicity.Teratogenic effects of thalidomide: molecular mechanisms.The gap junction as a "Biological Rosetta Stone": implications of evolution, stem cells to homeostatic regulation of health and disease in the Barker hypothesis.Thalidomide and lenalidomide: Mechanism-based potential drug combinations.Maternal factors, medications, and drug exposure in congenital limb reduction defects.The developing brain and the environment: an introductionThalidomide: a new anticancer drug?Thalidomide in dermatology: revisited.Shoulder joint replacement can improve quality of life and outcome in patients with dysmelia: a case series.In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems.Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase functionDetection and investigation of temporal clusters of congenital anomaly in Europe: seven years of experience of the EUROCAT surveillance system.New molecular targets in advanced prostate cancer.The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.New Findings in eNOS gene and Thalidomide Embryopathy Suggest pre-transcriptional effect variants as susceptibility factors.Considering the Embryopathogenesis of VACTERL AssociationPhocomelia: Case report and differential diagnosis.What can we learn from the thalidomide experience: an ophthalmologic perspective.Chiral recognition of amino acids by use of a fluorescent resorcinarene.Review paper: cancer stem cells and cancer nonstem cells: from adult stem cells or from reprogramming of differentiated somatic cells.Thalidomide and misoprostol: Ophthalmologic manifestations and associations both expected and unexpected.A safety assessment of tumor necrosis factor antagonists during pregnancy.Mental Disorders in People Affected by Thalidomide.
P2860
Q24289150-D2CD0802-8FF8-4C7C-A835-692910E99A5AQ24653215-AEFA6372-116C-4DF6-BB2F-6073531ABC83Q28085087-E5A5F94E-70DA-4F9B-829C-07FBB10EC5AAQ28244940-245FC4BB-893B-4DE9-B61C-424266F10C79Q28343365-DADD782C-0709-4029-AA11-32E020F0A95AQ28478928-353D8C70-71DF-464B-96AD-75652265C485Q28542006-D4BA88AA-55EA-455F-8449-42800BEF8E12Q28542980-32F17ED2-7034-4383-BA91-42F842E85CCFQ28543170-D78C5EFF-C90A-4F6E-B7E4-BAE455D74F58Q28751300-29980B31-59E0-4F63-980A-FF054C511CE8Q30490782-59E2176C-2271-42FC-8CAE-0CF90E334434Q31142527-7D3FDA48-6ABA-4B2E-9C77-475A04A5528DQ33363682-81F53D26-80CC-457F-8730-67DD85A6FABAQ33753486-B79E96A9-7F20-46B0-8CAD-D354CC51A5C5Q34179690-2F97EDD6-1299-4B77-AF18-87A6D805B394Q34263615-7255E01A-9FEA-4498-86EF-844CE885E9DAQ34343991-F8F05188-6774-47FD-B7B4-7C41E6C9C675Q34660391-547D8A19-1A5A-415D-BEC7-AC68E875AFB2Q34678350-396042D1-0AA6-4067-A69C-98F3BC0968E3Q34775475-664FC0FE-E983-4629-9758-AE0D8EBB1BD9Q34857730-8EC698F9-EBF0-40CD-9981-1E790BF80435Q35134560-E79DD1B2-981D-4E57-AA33-3E4EFE6E6B31Q35164773-1498A4A1-8620-4D39-8F22-0D679D1C2520Q35215252-39473CE7-39E8-4959-ACC7-5FE1D75E79E6Q36000164-C86B0084-A60D-481B-A653-F33FC00D4A8AQ36001001-BFDF3B02-D487-44D3-A471-D0446D4674C0Q36171864-5ABC4FAB-F50A-4082-A61C-8FAB05743F6FQ36299827-7E9BD5FE-1D9A-4444-A9D9-CA304799CF8BQ36386552-BDA1ADA8-14F2-454A-BB8D-33555A6688C0Q36532080-42F4A2D2-8E06-4638-84A3-18EAC37516FCQ36612613-CE4FC0CC-E18B-46EA-A0B5-FF02DD255B98Q36719295-9525E372-E6D8-4A7A-9976-78F3A3021811Q36802389-419489CE-D048-4499-9BFE-421742393AABQ36986650-C24B0572-5F50-48D9-8690-3D65E1A45122Q37019889-6030CD77-4882-409E-9674-16ECBE0C2B17Q37143909-A6370D74-689F-49A1-B7CD-64E8D4D5DEE7Q37406536-9BA60B9E-057E-4EF0-9A46-5A0595625293Q37565355-559E24AA-B1C2-4243-A3BF-69BF822DC95BQ37724349-ADBDC380-EBF7-404E-83F7-937F46B9A669Q37739184-7A94C4C8-39BB-4641-9E45-C055FD19787F
P2860
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
A short history of thalidomide embryopathy.
@en
A short history of thalidomide embryopathy.
@nl
type
label
A short history of thalidomide embryopathy.
@en
A short history of thalidomide embryopathy.
@nl
prefLabel
A short history of thalidomide embryopathy.
@en
A short history of thalidomide embryopathy.
@nl
P356
P1476
A short history of thalidomide embryopathy.
@en
P2093
P304
P356
10.1002/TERA.1420380303
P577
1988-09-01T00:00:00Z